Fundraising Fox
Allyx Therapeutics, Inc.
New Haven, US · Founded 2018 · Delaware corporation · 5 employees on LinkedIn · 4 known investors
Find your way into Allyx Therapeutics, Inc.
Sign up to see every warm intro you have to Allyx Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Allyx Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy acting at mGluR5, currently in Phase 1b clinical development for Alzheimer's disease.
Founders & leadership
Allyx Therapeutics, Inc. was founded in 2018 by Paul Fonteyne, Stephen Strittmatter, Stephen Bloch, Timothy Siegert, and Tim Siegert, PhD.
PF
SB
Stephen BlochCEO & Co-FounderStephen Bloch is CEO and co-founder of Allyx Therapeutics. He previously spent over 23 years as a General Partner at Canaan Partners investing in healthcare companies, served as CEO of RMS (a radiology benefits management company) for 6 years, and worked as a pharmaceutical strategy consultant at Arthur D. Little.
TS
Tim Siegert, PhDCOO & Co-Founder
JG
Jennifer GablerFinance ConsultantJennifer Gabler serves as an Executive Officer at Allyx Therapeutics. She previously held CFO positions at multiple venture-backed and biotech companies and co-founded Marlborough Street Partners, which provides strategic and operational services to investors and venture-funded enterprises.
Board
RA
GP
Investors · 4
Elm Street Ventures✓ confirmed by Allyx Therapeutics, Inc.New Haven · $250K – $1M
How we know: the company's own site · Elm Street Ventures's portfolio page · Not right? Tell us
Spring Mountain Capital✓ confirmed by Allyx Therapeutics, Inc.New York
How we know: the company's own site · Not right? Tell us
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · Not right? Tell us
WHINinferredNew York
How we know: board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$39.6M disclosed across 4 rounds · 2021–2026
▶$26.4MraisedMay 2026 · 32 investors · BiotechnologyRule 506(b)
▶$26.4MraisedMay 2026 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen BlochExecutive Officer, Director
- Stephen StrittmatterDirector
- Robert A BettigoleDirector
- Paul FonteyneDirector
- Gregory P HoDirector
- Timothy SiegertExecutive Officer
- Kevin L. RakinDirector
- Offering amount
- $30M
- Amount sold
- $26.4M
- Finders' fees
- $149.4K
- Placement agents
- Supervision Partners LLC
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedMar 2026 · 12 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMar 2026 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jennifer GablerExecutive Officer
- Robert A BettigoleDirector
- Paul FonteyneDirector
- Gregory P HoDirector
- Stephen StrittmatterDirector
- Stephen BlochExecutive Officer, Director
- Timothy SiegertExecutive Officer
- Offering amount
- $4M
- Amount sold
- $3.3M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2023 · 11 investors · BiotechnologyRule 506(b)
▶$2.3MraisedFeb 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert A. BettigoleDirector
- Stephen StrittmatterDirector
- Paul FonteyneDirector
- Gregory P. HoDirector
- Timothy SiegertExecutive Officer
- Stephen BlochExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$7.6MraisedJun 2021 · 10 investors · BiotechnologyRule 506(b)
▶$7.6MraisedJun 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory P. HoDirector
- Robert A. BettigoleDirector
- Stephen StrittmatterExecutive Officer, Director
- Stephen BlochExecutive Officer, Director
- Timothy SiegertExecutive Officer
- Paul FonteyneDirector
- Offering amount
- $8M
- Amount sold
- $7.6M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Allyx Therapeutics, Inc. went on to found or lead other companies.
Related companies · 6
AlloyAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
AmylyxAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Altay TherapeuticsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Allyx Therapeutics, Inc..
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $450K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Allyx Therapeutics, Inc. do?
- Allyx Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve and protect synapses in people with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy acting at mGluR5, currently in Phase 1b clinical development for Alzheimer's disease.
- Who founded Allyx Therapeutics, Inc.?
- Allyx Therapeutics, Inc. was founded by Paul Fonteyne, Stephen Strittmatter, Stephen Bloch, Timothy Siegert, Tim Siegert, PhD in 2018.
- Who are Allyx Therapeutics, Inc.'s investors?
- Allyx Therapeutics, Inc.'s investors include Elm Street Ventures, Spring Mountain Capital, Connecticut Innovations, WHIN.
- How much funding has Allyx Therapeutics, Inc. raised?
- Allyx Therapeutics, Inc. has disclosed $39.6M raised across 4 rounds.
- Where is Allyx Therapeutics, Inc. headquartered?
- Allyx Therapeutics, Inc. is headquartered in New Haven, US.